Posted by Michael Wonder on 01 Dec 2022
Livtencity (maribavir) receives positive CADTH recommendation for adults with post-transplant cytomegalovirus infection
1 December 2022 - The conditions for the positive recommendation is supported by the findings of the Phase 3 SOLSTICE trial.
Takeda Canada is pleased to announce that the Canada's CADTH Canadian Drug Expert Committee recommends Livtencity (maribavir) for public reimbursement.
